FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367304881> ?p ?o ?g. }

• W4367304881 abstract "<h3>Objective:</h3> This systematic review aims to explore the efficacy, safety, and tolerability of fenfluramine for seizure control in patients with Lennox-Gastaut syndrome (LGS). <h3>Background:</h3> Fenfluramine has been recently approved as an adjunctive medication for seizure control in patients with Lennox-Gastaut syndrome (LGS). Previously, it has been used in treatment of patients with Dravet syndrome. <h3>Design/Methods:</h3> We conducted a systematic literature search on MEDLINE, Cochrane, and EMBASE as per guidelines of Preferred Reporting Items for Systematic Reviews (PRISMA). Two clinical trials analysing the effects of different doses of fenfluramine were included in this review. <h3>Results:</h3> In a double-blind phase 3 randomised control trial (RCT), participants were randomised to receive fenfluramine (0.2 or 0.7mg/kg/d) or a placebo. In another open-label clinical trial (Lagae et al.), patients were administered fenfluramine with median dose being 0.4mg/kg/d. 50% or greater reduction in seizure frequency was assessed in both trials. The responder rate in the open-label trial was 62% at 20 weeks and 66.7% at 15 months, while responder rate in the RCT was also significant in both groups (28% in the 0.2mg/kg/day group and 25% in the 0.7mg/kg/day). The median percentage reduction in seizure frequency in the open-label trial was 53% in core and 58% in extension period, while 14.2% reduction in 0.2mg/kg/d and 26.5% reduction in 0.7mg/kg/d were reported in the RCT. Adverse effects were reported in 70% of patients in the open-label trial while the RCT reported ≥1 adverse effects in 78%, 90% and 75% of the participants from 0.2mg/kg/d, 0.7mg/kg/d and placebo groups, respectively. Adverse effects commonly seen were decreased appetite, somnolence, and fatigue. <h3>Conclusions:</h3> Adjunctive use of fenfluramine results in significant improvement in LGS patients refractory to standardised anti-seizure therapies. The side effects reported are usually mild. <b>Disclosure:</b> Mr. Qureshi has nothing to disclose. Ms. Kareem has nothing to disclose. Miss Mehdi has nothing to disclose. Miss Nadeem has nothing to disclose. Miss Majid has nothing to disclose. Dr. Hassan has nothing to disclose. Bakhtawar Ahmad has nothing to disclose. Mr. Aemaz Ur Rehman has nothing to disclose. Dr. Iftikhar has nothing to disclose. Dr. Khokhar has nothing to disclose." @default.
• W4367304881 created "2023-04-29" @default.
• W4367304881 creator A5001140856 @default.
• W4367304881 creator A5003402169 @default.
• W4367304881 creator A5011169990 @default.
• W4367304881 creator A5016606411 @default.
• W4367304881 creator A5032524280 @default.
• W4367304881 creator A5033267088 @default.
• W4367304881 creator A5049489840 @default.
• W4367304881 creator A5064922846 @default.
• W4367304881 creator A5067887366 @default.
• W4367304881 creator A5083495538 @default.
• W4367304881 date "2023-04-25" @default.
• W4367304881 modified "2023-09-30" @default.
• W4367304881 title "Efficacy and Safety of Fenfluramine in Lennox-Gastaut Syndrome: A Systematic Review (P13-1.007)" @default.
• W4367304881 doi "https://doi.org/10.1212/wnl.0000000000203586" @default.
• W4367304881 hasPublicationYear "2023" @default.
• W4367304881 type Work @default.
• W4367304881 citedByCount "0" @default.
• W4367304881 crossrefType "proceedings-article" @default.
• W4367304881 hasAuthorship W4367304881A5001140856 @default.
• W4367304881 hasAuthorship W4367304881A5003402169 @default.
• W4367304881 hasAuthorship W4367304881A5011169990 @default.
• W4367304881 hasAuthorship W4367304881A5016606411 @default.
• W4367304881 hasAuthorship W4367304881A5032524280 @default.
• W4367304881 hasAuthorship W4367304881A5033267088 @default.
• W4367304881 hasAuthorship W4367304881A5049489840 @default.
• W4367304881 hasAuthorship W4367304881A5064922846 @default.
• W4367304881 hasAuthorship W4367304881A5067887366 @default.
• W4367304881 hasAuthorship W4367304881A5083495538 @default.
• W4367304881 hasConcept C118552586 @default.
• W4367304881 hasConcept C126322002 @default.
• W4367304881 hasConcept C142724271 @default.
• W4367304881 hasConcept C168563851 @default.
• W4367304881 hasConcept C170493617 @default.
• W4367304881 hasConcept C187212893 @default.
• W4367304881 hasConcept C197934379 @default.
• W4367304881 hasConcept C204787440 @default.
• W4367304881 hasConcept C27081682 @default.
• W4367304881 hasConcept C2775864247 @default.
• W4367304881 hasConcept C2778186239 @default.
• W4367304881 hasConcept C2778375690 @default.
• W4367304881 hasConcept C2779307984 @default.
• W4367304881 hasConcept C2779638493 @default.
• W4367304881 hasConcept C2780623815 @default.
• W4367304881 hasConcept C3018162438 @default.
• W4367304881 hasConcept C535046627 @default.
• W4367304881 hasConcept C71924100 @default.
• W4367304881 hasConceptScore W4367304881C118552586 @default.
• W4367304881 hasConceptScore W4367304881C126322002 @default.
• W4367304881 hasConceptScore W4367304881C142724271 @default.
• W4367304881 hasConceptScore W4367304881C168563851 @default.
• W4367304881 hasConceptScore W4367304881C170493617 @default.
• W4367304881 hasConceptScore W4367304881C187212893 @default.
• W4367304881 hasConceptScore W4367304881C197934379 @default.
• W4367304881 hasConceptScore W4367304881C204787440 @default.
• W4367304881 hasConceptScore W4367304881C27081682 @default.
• W4367304881 hasConceptScore W4367304881C2775864247 @default.
• W4367304881 hasConceptScore W4367304881C2778186239 @default.
• W4367304881 hasConceptScore W4367304881C2778375690 @default.
• W4367304881 hasConceptScore W4367304881C2779307984 @default.
• W4367304881 hasConceptScore W4367304881C2779638493 @default.
• W4367304881 hasConceptScore W4367304881C2780623815 @default.
• W4367304881 hasConceptScore W4367304881C3018162438 @default.
• W4367304881 hasConceptScore W4367304881C535046627 @default.
• W4367304881 hasConceptScore W4367304881C71924100 @default.
• W4367304881 hasLocation W43673048811 @default.
• W4367304881 hasOpenAccess W4367304881 @default.
• W4367304881 hasPrimaryLocation W43673048811 @default.
• W4367304881 hasRelatedWork W2077441406 @default.
• W4367304881 hasRelatedWork W2090699703 @default.
• W4367304881 hasRelatedWork W2518276265 @default.
• W4367304881 hasRelatedWork W2755222529 @default.
• W4367304881 hasRelatedWork W2793900558 @default.
• W4367304881 hasRelatedWork W3137407127 @default.
• W4367304881 hasRelatedWork W4297175748 @default.
• W4367304881 hasRelatedWork W4309466939 @default.
• W4367304881 hasRelatedWork W4313311983 @default.
• W4367304881 hasRelatedWork W4318027231 @default.
• W4367304881 isParatext "false" @default.
• W4367304881 isRetracted "false" @default.
• W4367304881 workType "article" @default.